Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Market Analysis & Valuation

UpdatedJan 12, 2026
DataAggregated Company Financials
Companies134
  • 7D4.4%
  • 3M9.5%
  • 1Y-17.0%
  • YTD6.8%

The market has climbed 4.4% in the last 7 days, lead by the Healthcare sector with a gain of 8.5%. In contrast, the market has seen a decline of 17% over the last 12 months. Looking forward, earnings are forecast to grow by 5.9% annually.

Trending IndustriesBiotech

Market Valuation and Performance

Has the Danish Market valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 12 Jan 2026DKK 4.5tDKK 2.0tDKK 261.1b16.5x17.1x2.3x
Wed, 10 Dec 2025DKK 4.0tDKK 2.0tDKK 261.0b14.5x15.3x2x
Fri, 07 Nov 2025DKK 3.9tDKK 2.0tDKK 273.5b14.6x14.4x2x
Sun, 05 Oct 2025DKK 4.1tDKK 1.9tDKK 287.3b15.1x14.2x2.1x
Tue, 02 Sep 2025DKK 4.1tDKK 1.9tDKK 287.0b15x14.2x2.1x
Thu, 31 Jul 2025DKK 3.9tDKK 1.9tDKK 263.0b15.6x14.9x2.1x
Sat, 28 Jun 2025DKK 4.4tDKK 1.9tDKK 261.8b15.4x16.7x2.4x
Mon, 26 May 2025DKK 4.4tDKK 1.9tDKK 264.0b15.5x16.7x2.4x
Wed, 23 Apr 2025DKK 4.0tDKK 1.9tDKK 258.6b13.8x15.4x2.1x
Fri, 21 Mar 2025DKK 5.0tDKK 1.9tDKK 260.5b15.3x19x2.6x
Sun, 16 Feb 2025DKK 5.0tDKK 1.9tDKK 263.5b13.7x19x2.7x
Tue, 14 Jan 2025DKK 5.2tDKK 1.8tDKK 237.6b13.6x21.8x2.9x
Thu, 12 Dec 2024DKK 6.0tDKK 1.8tDKK 237.8b14.2x25.4x3.3x
Sat, 09 Nov 2024DKK 5.8tDKK 1.8tDKK 235.7b14.3x24.8x3.2x
Mon, 07 Oct 2024DKK 6.0tDKK 1.7tDKK 180.2b15.7x33.3x3.4x
Wed, 04 Sep 2024DKK 6.7tDKK 1.7tDKK 180.3b15.2x37.1x3.8x
Fri, 02 Aug 2024DKK 6.7tDKK 1.7tDKK 185.7b15.3x35.9x3.9x
Sun, 30 Jun 2024DKK 7.0tDKK 1.7tDKK 184.8b15.8x37.8x4.1x
Tue, 28 May 2024DKK 6.7tDKK 1.7tDKK 184.6b15.4x36.2x3.9x
Thu, 25 Apr 2024DKK 6.4tDKK 1.7tDKK 192.0b14.5x33.2x3.7x
Sat, 23 Mar 2024DKK 6.5tDKK 1.7tDKK 192.3b14.6x33.7x3.8x
Mon, 19 Feb 2024DKK 6.3tDKK 1.7tDKK 190.3b13.8x33.1x3.7x
Wed, 17 Jan 2024DKK 5.7tDKK 1.8tDKK 217.1b13.6x26.5x3.2x
Fri, 15 Dec 2023DKK 5.3tDKK 1.8tDKK 216.2b13.3x24.7x3x
Sun, 12 Nov 2023DKK 5.3tDKK 1.8tDKK 218.1b12.5x24.2x3x
Tue, 10 Oct 2023DKK 5.2tDKK 1.9tDKK 284.7b13.1x18.2x2.7x
Thu, 07 Sep 2023DKK 5.4tDKK 1.9tDKK 284.8b12.7x18.9x2.8x
Sat, 05 Aug 2023DKK 4.9tDKK 1.9tDKK 322.1b13.5x15.3x2.6x
Mon, 03 Jul 2023DKK 5.1tDKK 1.9tDKK 322.2b13.8x15.8x2.6x
Wed, 31 May 2023DKK 5.1tDKK 1.9tDKK 325.4b14.2x15.8x2.6x
Fri, 28 Apr 2023DKK 5.0tDKK 1.9tDKK 343.5b15.3x14.6x2.6x
Sun, 26 Mar 2023DKK 4.8tDKK 1.9tDKK 346.9b14x13.9x2.5x
Tue, 21 Feb 2023DKK 4.8tDKK 1.9tDKK 347.1b14.1x13.9x2.5x
Thu, 19 Jan 2023DKK 4.7tDKK 1.9tDKK 355.9b13.8x13.2x2.5x
Price to Earnings Ratio

13.2x


Total Market Cap: DKK 4.7tTotal Earnings: DKK 355.9bTotal Revenue: DKK 1.9tTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Market Price to Earnings3Y Average 22.2x202420252026
Current Market PE
  • Investors are pessimistic on the Danish market, indicating that they anticipate earnings will not grow as fast as they have historically.
  • The market is trading at a PE ratio of 17.1x which is lower than its 3-year average PE of 22.2x.
Past Earnings Growth
  • The earnings for Danish listed companies have declined 9.8% per year over the last three years.
  • Meanwhile revenues have been flat.
  • This means that either the cost of doing business or the level of investment back into businesses is increasing since sales have remained steady while profits have fallen.

Sector Trends

Which sectors have driven the changes within the Danish Market?

DK Market4.41%
Energy15.65%
Healthcare8.53%
Materials6.44%
Telecom3.98%
Consumer Staples3.48%
Real Estate1.51%
Industrials1.30%
Tech1.27%
Utilities0.89%
Financials-2.24%
Consumer Discretionary-10.15%
Sector PE
  • Investors favour the Tech sector the most for future growth, which is trading above its 3-year average PE ratio of 52.1x.
    • The market's confidence is likely because analysts are expecting annual earnings growth of 56.7% which is higher than its past year's earnings decline of 17.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Tech sector, expecting annual earnings growth of 57% over the next 5 years.
  • This is better than its past earnings decline of 17% per year.
  • In contrast, the Energy sector is expected to see its earnings decline by 35% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuationSector
NOVO B Novo NordiskDKK 381.4510.0%
+DKK 154.2b		-37.8%PE16.3xHealthcare
NSIS B NovozymesDKK 421.806.5%
+DKK 12.1b		5.2%PE48xMaterials
DSV DSVDKK 1.68k3.0%
+DKK 11.7b		11.4%PE41.9xIndustrials
GMAB GenmabDKK 2.18k8.6%
+DKK 10.6b		39.6%PE13.2xHealthcare
COLO B ColoplastDKK 566.004.4%
+DKK 5.4b		-29.0%PE35.1xHealthcare
See more

Market Insights

Header cover image
Which Markets Will Sink or Swim in 2026? 🌍
Richard Bowman avatar
Richard Bowman
|
|
What research teams agree on – and where they don’t – heading into 2026.
Continue reading
Three Sectors Expected to Rally in 2026 📈
Last Week

Three Sectors Expected to Rally in 2026 📈

Latest News

PNDORA
DKK 588.40
Pandora
7D
-13.1%
1Y
-53.7%
DSV
DKK 1,681.50
DSV
7D
3.0%
1Y
11.4%

DSV A/S' (CPH:DSV) Popularity With Investors Is Clear

Jan 12
DSV A/S' (CPH:DSV) Popularity With Investors Is Clear
NKT
DKK 813.00
NKT
7D
-1.5%
1Y
64.6%

Here's Why We Think NKT (CPH:NKT) Might Deserve Your Attention Today

Jan 11
Here's Why We Think NKT (CPH:NKT) Might Deserve Your Attention Today
HLUN B
DKK 44.84
H. Lundbeck
7D
5.3%
1Y
13.2%

HLUN B: Pipeline Progress And Partnerships Will Support Balanced Medium Term Outlook

Analysts have trimmed their price target for H. Lundbeck to €45.55 from €48.18, reflecting updated views on slightly softer revenue growth assumptions, a modestly higher discount rate, a small uplift in expected profit margins, and a lower future P/E multiple.
ZEAL
DKK 419.90
Zealand Pharma
7D
-6.1%
1Y
-39.9%

ZEAL: Metabolic Collaboration Will Support Future Upside Despite Trimmed Fair Value

Analysts have trimmed their price target on Zealand Pharma to approximately $746 from about $774, citing a slightly higher discount rate and revenue growth headwinds, partially offset by a modestly improved profit margin and a higher assumed future P/E multiple. What's in the News OTR Therapeutics and Zealand Pharma A/S entered into a multi program collaboration and license agreement to discover and develop therapeutics for metabolic diseases, combining Zealand Pharma's obesity and metabolic health expertise with OTR Therapeutics' R&D platform (Key Developments).
COLO B
DKK 566.00
Coloplast
7D
4.4%
1Y
-29.0%

COLO B: Sustained Margins And Dividend Payouts Will Support Future Upside

Narrative update The analyst price target for Coloplast has edged up by about DKK 0.30 to reflect slightly higher fair value estimates. Recent Street research shows a mix of views, with some analysts lifting targets toward DKK 535 and others resetting them closer to DKK 640, which has led to modest adjustments to discount rate, revenue growth, profit margin, and future P/E assumptions.
NOVO B
DKK 381.45
Novo Nordisk
7D
10.0%
1Y
-37.8%

NOVO B: Future Returns Will Rely On Oral Obesity Treatment And Legal Risks

Narrative Update Analysts have nudged their fair value estimate for Novo Nordisk slightly lower, from $393.04 to $392.29, as small adjustments to revenue growth, profit margin, and future P/E assumptions result in a marginally reduced price target. Analyst Commentary Recent tweaks to fair value for Novo Nordisk reflect relatively modest shifts in assumptions rather than a major change in the overall thesis.
DANSKE
DKK 313.70
Danske Bank
7D
-2.9%
1Y
47.9%

DANSKE: Future Returns Will Reflect Earnings Durability And Easing Legal Overhang

Analysts have nudged their fair value estimate for Danske Bank up from DKK 308 to DKK 310, reflecting a series of recent price target increases (including moves to DKK 295 and DKK 319) and small adjustments in discount rate, profit margin and forward P/E assumptions. Analyst Commentary Recent research on Danske Bank has centered on a cluster of price target revisions, with several large firms updating their views within a short period.
JYSK
DKK 870.00
Jyske Bank
7D
-1.8%
1Y
66.0%

JYSK: Updated Profit Outlook And Lower Discount Rate Will Shape Fair Value

Analysts have raised their fair value estimate for Jyske Bank from DKK 750.00 to DKK 865.00, citing updated assumptions for the discount rate, revenue trends, profit margin profile, and future P/E levels. What's in the News Jyske Bank A/S updated its 2025 earnings guidance, now expecting net profit of DKK 4.9b to DKK 5.3b, compared with earlier guidance at the upper end of DKK 3.8b to DKK 4.6b (company guidance).
DEMANT
DKK 224.20
Demant
7D
3.8%
1Y
-20.8%

DEMANT: Future Earnings Resilience Will Rely On Stable Market Position

Analysts have trimmed their price target on Demant slightly from DKK 271.65 to DKK 268. This reflects modestly softer assumptions for revenue growth and future P/E, partly offset by a marginally higher expected profit margin and recent views that organic revenue share gains may be limited for now.
RILBA
DKK 1,531.00
Ringkjøbing Landbobank
7D
-2.3%
1Y
28.4%
CARL B
DKK 845.20
Carlsberg
7D
4.2%
1Y
25.9%

CARL B: Overweight Upgrade Signals Stronger Beer Sector Support Into 2026

Analysts have raised their price target for Carlsberg to DKK 975 from DKK 850, citing more supportive views on the beer sector heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Carlsberg, using the higher DKK 975 price target to frame what they see as an improved setup for the shares heading into 2026.
GMAB
DKK 2,182.00
Genmab
7D
8.6%
1Y
39.6%

GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing

Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).
ALSYDB
DKK 545.00
AL Sydbank
7D
-4.5%
1Y
44.0%

Industry Analysts Just Made A Stunning Upgrade To Their AL Sydbank A/S (CPH:ALSYDB) Revenue Forecasts

Dec 14
Industry Analysts Just Made A Stunning Upgrade To Their AL Sydbank A/S (CPH:ALSYDB) Revenue Forecasts
TRYG
DKK 159.20
Tryg
7D
-1.5%
1Y
4.7%
NSIS B
DKK 421.80
Novozymes
7D
6.5%
1Y
5.2%